AAAAAA

   
Results: 1-25 |
Results: 25
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)
Authors: Chauret, N Yergey, JA Brideau, C Friesen, RW Mancini, J Riendeau, D Silva, J Styhler, A Trimble, LA Nicoll-Griffith, DA
Citation: N. Chauret et al., In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663), BIOORG MED, 11(8), 2001, pp. 1059-1062
Urogenital distribution of a mouse membrane-associated prostaglandin E-2 synthase
Authors: Guan, YF Zhang, YH Schneider, A Riendeau, D Mancini, JA Davis, L Komhoff, M Breyer, RM Breyer, MD
Citation: Yf. Guan et al., Urogenital distribution of a mouse membrane-associated prostaglandin E-2 synthase, AM J P-REN, 281(6), 2001, pp. F1173-F1177
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
Authors: Ouellet, M Riendeau, D Percival, MD
Citation: M. Ouellet et al., A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin, P NAS US, 98(25), 2001, pp. 14583-14588
Etoricoxib (MK-0663): Preclinical profile and comparison with other agentsthat selectively inhibit cyclooxygenase-2
Authors: Riendeau, D Percival, MD Brideau, C Charleson, S Dube, D Ethier, D Falgueyret, JP Friesen, RW Gordon, R Greig, G Guay, J Mancini, J Ouellet, M Wong, E Xu, L Boyce, S Visco, D Girard, Y Prasit, P Zamboni, R Rodger, IW Gresser, M Ford-Hutchinson, AW Young, RN Chan, CC
Citation: D. Riendeau et al., Etoricoxib (MK-0663): Preclinical profile and comparison with other agentsthat selectively inhibit cyclooxygenase-2, J PHARM EXP, 296(2), 2001, pp. 558-566
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of humancathepsins K and L
Authors: Falgueyret, JP Oballa, RM Okamoto, O Wesolowski, G Aubin, Y Rydzewski, RM Prasit, P Riendeau, D Rodan, SB Percival, MD
Citation: Jp. Falgueyret et al., Novel, nonpeptidic cyanamides as potent and reversible inhibitors of humancathepsins K and L, J MED CHEM, 44(1), 2001, pp. 94-104
Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis
Authors: Mancini, JA Blood, K Guay, J Gordon, R Claveau, D Chan, CC Riendeau, D
Citation: Ja. Mancini et al., Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis, J BIOL CHEM, 276(6), 2001, pp. 4469-4475
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits
Authors: Wong, E Huang, JQ Tagari, P Riendeau, D
Citation: E. Wong et al., Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits, ATHEROSCLER, 157(2), 2001, pp. 393-402
Mutations of the C-terminal end of cathepsin K affect proenzyme secretion and intracellular maturation
Authors: Claveau, D Riendeau, D
Citation: D. Claveau et D. Riendeau, Mutations of the C-terminal end of cathepsin K affect proenzyme secretion and intracellular maturation, BIOC BIOP R, 281(2), 2001, pp. 551-557
LTA(4)-derived 5-oxo-eicosatetraenoic acid: pH-dependent formation and interaction with the LTB4 receptor of human polymorphonuclear leukocytes
Authors: Falgueyret, JP Riendeau, D
Citation: Jp. Falgueyret et D. Riendeau, LTA(4)-derived 5-oxo-eicosatetraenoic acid: pH-dependent formation and interaction with the LTB4 receptor of human polymorphonuclear leukocytes, BBA-MOL C B, 1484(1), 2000, pp. 51-58
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx (TM))
Authors: Nicoll-Griffith, DA Yergey, JA Trimble, LA Silva, JM Li, C Chauret, N Gauthier, JY Grimm, E Leger, S Roy, P Therien, M Wang, ZY Prasit, P Zamboni, R Young, RN Brideau, C Chan, CC Mancini, J Riendeau, D
Citation: Da. Nicoll-griffith et al., Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx (TM)), BIOORG MED, 10(23), 2000, pp. 2683-2686
Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells
Authors: Claveau, D Riendeau, D Mancini, JA
Citation: D. Claveau et al., Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells, BIOCH PHARM, 60(6), 2000, pp. 759-769
Cloning and expression of rhesus monkey cathepsin K
Authors: Guay, J Riendeau, D Mancini, JA
Citation: J. Guay et al., Cloning and expression of rhesus monkey cathepsin K, BONE, 25(2), 1999, pp. 205-209
A new structural variation on the methanesulfonylphenyl class of selectivecyclooxygenase-2 inhibitors
Authors: Li, CS Black, WC Brideau, C Chan, CC Charleson, S Cromlish, WA Claveau, D Gauthier, JY Gordon, R Greig, G Grimm, E Guay, J Lau, CK Riendeau, D Therien, M Visco, DM Wong, E Xu, LJ Prasit, P
Citation: Cs. Li et al., A new structural variation on the methanesulfonylphenyl class of selectivecyclooxygenase-2 inhibitors, BIOORG MED, 9(22), 1999, pp. 3181-3186
Synthesis and biological evaluation of 3-heteroarizoxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors
Authors: Lau, CK Brideau, C Chan, CC Charleson, S Cromlish, WA Ethier, D Gauthier, JY Gordon, R Guay, J Kargman, S Li, CS Prasit, P Riendeau, D Therien, M Visco, DM Xu, LJ
Citation: Ck. Lau et al., Synthesis and biological evaluation of 3-heteroarizoxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors, BIOORG MED, 9(22), 1999, pp. 3187-3192
Substituted heterocyclic analogs as selective COX-2 inhibitors in the Flosulide class
Authors: Ouimet, N Chan, CC Charleson, S Claveau, D Gordon, R Guay, D Li, CS Ouellet, M Percival, DM Riendeau, D Wong, E Zamboni, R Prasit, P
Citation: N. Ouimet et al., Substituted heterocyclic analogs as selective COX-2 inhibitors in the Flosulide class, BIOORG MED, 9(2), 1999, pp. 151-156
Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors
Authors: Frenette, R Hutchinson, JH Leger, S Therien, M Brideau, C Chan, CC Charleson, S Ethier, D Guay, J Jones, TR McAuliffe, M Piechuta, H Riendeau, D Tagari, P Girard, Y
Citation: R. Frenette et al., Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors, BIOORG MED, 9(16), 1999, pp. 2391-2396
Sar in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor
Authors: Leblanc, Y Roy, P Boyce, S Brideau, C Chan, CC Charleson, S Gordon, R Grimm, E Guay, J Leger, S Li, CS Riendeau, D Visco, D Wang, Z Webb, J Xu, LJ Prasit, P
Citation: Y. Leblanc et al., Sar in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor, BIOORG MED, 9(15), 1999, pp. 2207-2212
The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Authors: Prasit, P Wang, Z Brideau, C Chan, CC Charleson, S Cromlish, W Ethier, D Evans, JF Ford-Hutchinson, AW Gauthier, JY Gordon, R Guay, J Gresser, M Kargman, S Kennedy, B Leblanc, Y Leger, S Mancini, J O'Neill, GP Ouellet, M Percival, MD Perrier, H Riendeau, D Rodger, I Tagari, P Therien, M Vickers, P Wong, E Xu, LJ Young, RN Zamboni, R Boyce, S Rupniak, N Forrest, N Visco, D Patrick, D
Citation: P. Prasit et al., The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, BIOORG MED, 9(13), 1999, pp. 1773-1778
2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridinesas selective and orally active cyclooxygenase-2 inhibitors
Authors: Dube, D Brideau, C Deschenes, D Fortin, R Friesen, RW Gordon, R Girard, Y Riendeau, D Savoie, C Chan, CC
Citation: D. Dube et al., 2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridinesas selective and orally active cyclooxygenase-2 inhibitors, BIOORG MED, 9(12), 1999, pp. 1715-1720
Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor
Authors: Nicoll-Griffith, DA Falgueyret, JP Silva, JM Morin, PE Trimble, L Chan, CC Clas, S Leger, S Wang, ZY Yergey, JA Riendeau, D
Citation: Da. Nicoll-griffith et al., Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor, DRUG META D, 27(3), 1999, pp. 403-409
Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
Authors: Chan, CC Boyce, S Brideau, C Charleson, S Cromlish, W Ethier, D Evans, J Ford-Hutchinson, AW Forrest, MJ Gauthier, JY Gordon, R Gresser, M Guay, J Kargman, S Kennedy, B Leblanc, Y Leger, S Mancini, J O'Neill, GP Ouellet, M Patrick, D Percival, MD Perrier, H Prasit, P Rodger, I Tagari, P Therien, M Vickers, P Visco, D Wang, Z Webb, J Wong, E Xu, LJ Young, RN Zamboni, R Riendeau, D
Citation: Cc. Chan et al., Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J PHARM EXP, 290(2), 1999, pp. 551-560
2,3-diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors
Authors: Black, WC Brideau, C Chan, CC Charleson, S Chauret, N Claveau, D Ethier, D Gordon, R Greig, G Guay, J Hughes, G Jolicoeur, P Leblanc, Y Nicoll-Griffith, D Ouimet, N Riendeau, D Visco, D Wang, ZY Xu, L Prasit, P
Citation: Wc. Black et al., 2,3-diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors, J MED CHEM, 42(7), 1999, pp. 1274-1281
Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B-4 biosynthesis in human polymorphonuclear leukocytes
Authors: Denis, D Riendeau, D
Citation: D. Denis et D. Riendeau, Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B-4 biosynthesis in human polymorphonuclear leukocytes, EUR J PHARM, 367(2-3), 1999, pp. 343-350
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
Authors: Ehrich, EW Dallob, A De Lepeleire, I Van Hecken, A Riendeau, D Yuan, WY Porras, A Wittreich, J Seibold, JR De Schepper, P Mehlisch, DR Gertz, BJ
Citation: Ew. Ehrich et al., Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model, CLIN PHARM, 65(3), 1999, pp. 336-347
Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein
Authors: Mancini, JA Waterman, H Riendeau, D
Citation: Ja. Mancini et al., Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein, J BIOL CHEM, 273(49), 1998, pp. 32842-32847
Risultati: 1-25 |